Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future

Table 2

Comparison of clinical outcomes of ASCT according to different age groups.

Authors (year)	Median age; (range)	Number of; patients	Conditioning; regimen	TRM	CR	Median; PFS	Median; OS
Siegel et al., (1999) [23]	52 (37–64)	49	MEL 200	2%	43%	34 mo	58 mo
	67 (65–76)	49		8%	20%*	18 mo	40 mo
Sirohi et al., (2000) [24]	55 (31–64)	17	MEL 200	12%	47%	23 mo	36 mo
	67 (65–74)	17		18%	35%	24 mo	43 mo
Reece et al., (2003) [25]	52 (30–59)	382	MEL ± TBI and others	6%	34%	27 mo	39 mo
	63 (60–73)	110		5%	33%	24 mo	39 mo
Jantunen et al., (2006) [26]	57 (39–64)	79	MEL 200	1%	36%	21 mo	66 mo
	68 (65–73)	22		0%	44%	23 mo	57 mo
Gertz et al., (2007) [27]	≤65	541	MEL 200	3%	30%	17 mo	44 mo
	>65	137	MEL 140–200	3%	40%	17 mo	44 mo
Kumar et al., (2008) [28]	56 (37–65)	60	MEL 200	0%	28%	18 mo	53 mo
	72 (70–76)	33	MEL 140–200	3%	42%	29 mo	NR
El Cheikh et al., (2011) [29]	62 (60–65)	104	MEL 140–200	4%	48%	45 mo	57% at 5 yr
	69 (65–77)	82	MEL 100–200	4%	41%	27 mo**	54% at 5 yr
Muta et al., (2013) [30]	60 (51–64)	63	MEL 180–200	3%	24%	21 mo	73 mo
	67 (65–76)	25	MEL 100–200	4%	12%	17 mo	41 mo

TRM: treatment-related mortality; CR: complete response; PFS: progression-free survival; OS: overall survival; MEL: melphalan; TBI: total body irradiation; mo: months; yr: years; NR: not reached.
^∗𝑃=0.02, ^∗∗𝑃<0.0001.